Free Trial

Deutsche Bank AG Grows Holdings in QIAGEN N.V. (NYSE:QGEN)

QIAGEN logo with Medical background

Key Points

  • Deutsche Bank AG increased its ownership in QIAGEN N.V. by 57.5%, acquiring 1,639,621 shares, bringing its total to 4,491,131 shares worth approximately $180.3 million.
  • QIAGEN reported a quarterly earnings of $0.60 per share, matching analysts' expectations, with a revenue of $533.54 million, reflecting a 7.7% increase year-over-year.
  • The company announced a dividend of $0.25 per share, which translates to a strong dividend yield of 52.0% and a payout ratio of 14.79%.
  • Need Better Tools to Track Qiagen? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Deutsche Bank AG increased its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 57.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 4,491,131 shares of the company's stock after purchasing an additional 1,639,621 shares during the period. Deutsche Bank AG owned 2.02% of QIAGEN worth $180,319,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd purchased a new position in shares of QIAGEN during the first quarter worth about $94,000. Tower Research Capital LLC TRC grew its stake in shares of QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the period. Federated Hermes Inc. acquired a new position in shares of QIAGEN in the first quarter valued at approximately $150,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of QIAGEN during the fourth quarter worth approximately $202,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on QGEN. Wall Street Zen upgraded shares of QIAGEN from a "buy" rating to a "strong-buy" rating in a research report on Sunday, August 3rd. Cowen reiterated a "hold" rating on shares of QIAGEN in a research note on Thursday. Barclays started coverage on shares of QIAGEN in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Bank of America boosted their target price on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, UBS Group increased their target price on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday. Eight research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $49.69.

View Our Latest Report on QGEN

QIAGEN Price Performance

Shares of QGEN traded down $0.34 on Friday, reaching $48.02. The stock had a trading volume of 1,293,968 shares, compared to its average volume of 1,636,041. QIAGEN N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The firm has a market capitalization of $10.67 billion, a PE ratio of 28.37, a PEG ratio of 2.45 and a beta of 0.64. The firm has a 50-day moving average of $48.02 and a 200 day moving average of $43.54. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%. The company had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the business earned $0.55 earnings per share. QIAGEN's quarterly revenue was up 7.7% compared to the same quarter last year. Sell-side analysts expect that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Announces Dividend

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a $0.25 dividend. This represents a dividend yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is 14.79%.

About QIAGEN

(Free Report)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Further Reading

Institutional Ownership by Quarter for QIAGEN (NYSE:QGEN)

Should You Invest $1,000 in Qiagen Right Now?

Before you consider Qiagen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.

While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines